Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 17/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 13/20 | 0.70 |
| ▸ | HTR2B | P41595 | 6/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.70 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.63 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.63 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29575011 | 1.00 | ADORA3 (0.70) | ADORA3ADORA1HTR2BSLC6A3HSP90B1 | |
| SCHEMBL29573850 | 0.94 | ADORA3 (0.63) | ADORA3ADORA1HTR2BSLC6A3HSP90B1 | |
| SCHEMBL29573481 | 0.94 | ADORA3 (0.70) | ADORA3ADORA1HTR2BSLC6A3HSP90B1 | |
| SCHEMBL29573284 | 0.90 | ADORA3 (0.62) | ADORA3ADORA1HTR2BSLC6A3HSP90B1 | |
| SCHEMBL29573830 | 0.90 | ADORA3 (0.62) | ADORA3ADORA1HTR2BSLC6A3HSP90B1 | |
| SCHEMBL29574083 | 0.88 | ADORA3 (0.63) | ADORA3ADORA1HTR2BSLC6A3HSP90B1 | |
| SCHEMBL29573974 | 0.86 | HSP90B1 (0.69) | ADORA3ADORA1HTR2BSLC6A3HSP90B1 | |
| SCHEMBL29574286 | 0.84 | HSP90B1 (0.74) | ADORA3ADORA1HTR2BHSP90B1TMIGD3 | |
| SCHEMBL29574318 | 0.84 | ADORA3 (0.53) | ADORA3ADORA1HTR2BSLC6A3HSP90B1 | |
| SCHEMBL29574049 | 0.81 | ADORA3 (0.72) | ADORA3ADORA1HTR2BSLC6A3HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416245-A1 | ADENOSINE ANALOGS FOR THE TREATMENT OF DISEASE | BIOINTERVENE, INC. | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416245-A1 | ADENOSINE ANALOGS FOR THE TREATMENT OF DISEASE | ADORA2A, ADA, ADORA2B | ADORA3 5/4885ADORA1 6/4885HTR2B 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.